Phase II trial of suramin in patients with metastatic renal cell carcinoma

Investigational New Drugs

Volumn 17, Issue 2, 1999, Pages 183-186

  Dreicer, Robert ^a,b,d   Smith, David C ^c   Williams, Richard D ^a,b   See, William A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Carcinoma; Neoplasm metastasis; Renal cell; Suramin

Indexed keywords

SURAMIN;

ADRENAL METASTASIS; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOXICITY; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURAMIN; TREATMENT OUTCOME;

EID: 0032785794     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006331518952     Document Type: Article

References (11)

1. Couillard DR, deVere White RW: Surgery of renal cell carcinoma. Urol Clin North Am 20: 263-275, 1993
2. Motzer RJ, Bander NH, Nanus DM: Renal cell carcinoma. N Engl J Med 335: 865-875, 1996
3. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 338: 1272-1278, 1998
4. Hawking F: Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother 15: 289-322, 1978
5. Small EJ, Marshall ME, Reyno L, Meyers F, Natale R, Meyer M, Lenehan P, Chen L, Eisenberger M: Superiority of suramin + hydrocortisone over placebo + hydrocortisone: results of a multi-center double-blind phase ni study in patients with hormone refractory prostate cancer (abstract). Proc Am Soc Clin Oncol 17: 308a, 1998
6. Stein CA, La Rocca RV, Thomas R, McAtee N, Meyers CE: Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7: 499-508, 1989
7. Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, Zuhowski EG, Lowitt MH, Jacobs SC, Egorin MJ: Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst 85: 611-612, 1993
8. Reyno LM, Egorin MJ, Eisenberger MA, Sinibaldi VJ, Sridhara R, Zuhowski EG, Van Echo DA: Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. Proc Am Soc Clin Oncol 12: 135, 1993
9. La Rocca RV, Stein CA, Danesi R, Cooper MR, Uhrich M, Myers CE: A pilot study of suramin in the treatment of metastatic renal cell carcinoma. Cancer 67: 1509-1513, 1991
10. Motzer RJ, Nanus DM, O'Moore P, Scher IH, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albine AP, Bosl GJ: Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res 52: 5775-5779, 1992
11. Gleave ME, Elhilahi M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A, The Canadian Urologie Oncology Group: Interferon gamma-1b compared with placebo in metastatic renal cell carcinoma. N Engl J Med 338: 1265-1271, 1998